Jason A. Chesney, M.D., Ph.D.

• Professor of Medicine, Pharmacology and Toxicology, Biochemistry and Molecular Biology
• Chief, Division of Medical Oncology and Hematology
• Director, UofL Health - Brown Cancer Center
• Associate Vice President for Health Affairs
• Medical Director, Clinical Trials Office, UofL Health - Brown Cancer Center
• Associate Director, Translational Research Program, UofL Health - Brown Cancer Center
• Brown Foundation Chair

UofL Health - Brown Cancer Center
529 South Jackson Street
Louisville, KY 40202

502-562-4585 - Academic Office
502-562-4370 - Patient Appointments

Education and Training

• Medical School: University of Minnesota
• Residency: Memorial Sloan-Kettering Cancer Center
• Fellowship: Cornell University Medical College
• Ph.D.: University of Minnesota

Get To Know Dr. Chesney

Featured Publications

• Robert C, Gastman B, Gogas H, Rutkowski P, Long GV, Chaney MF, Joshi H, Lin YL, Snyder W, Chesney JA. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. Eur J Cancer. 2024 May 15;207:114120. doi: 10.1016/j.ejca.2024.114120. Epub ahead of print. PMID: 38870745.
• Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J Immunother Cancer. 2024 Apr 18;12(4):e008378. doi: 10.1136/jitc-2023-008378. PMID: 38641350; PMCID: PMC11029323.
• Gosser C, Al Bawaliz A, Bahaj W, Chesney J, Ranjan S. Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap. Cureus. 2023 Nov 18;15(11):e49007. doi: 10.7759/cureus.49007. PMID: 38111441; PMCID: PMC10726830.
• Katiyar V, Chesney J, Kloecker G. Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy. Cancers (Basel). 2023 Jul 23;15(14):3733. doi: 10.3390/cancers15143733. PMID: 37509394; PMCID: PMC10377757.
• Sarkar OS, Donninger H, Al Rayyan N, Chew LC, Stamp B, Zhang X, Whitt A, Li C, Hall M, Mitchell RA, Zippelius A, Eaton J, Chesney JA, Yaddanapudi K. Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy. Sci Adv. 2023 Jun 30;9(26):eadg3736. doi: 10.1126/sciadv.adg3736. Epub 2023 Jun 30. PMID: 37390211; PMCID: PMC10313166.
• Nguyen TQ, Schneider G, Kaliappan A, Buscaglia R, Brock GN, Hall MB, Miller DM, Chesney JA, Garbett NC. Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients. Curr Oncol. 2023 Jun 24;30(7):6079-6096. doi: 10.3390/curroncol30070453. PMID: 37504313; PMCID: PMC10378067.
• Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer. 2023 May;11(5):e006270. doi: 10.1136/jitc-2022-006270. PMID: 37142291; PMCID: PMC10163510.
• Maharaj S, Jain N, Al Bawaliz A, Miller D, Chesney J. Melanoma of unknown primary: favorable survival persists in the immunotherapy era. Int J Dermatol. 2023 Apr;62(4):e236-e238. doi: 10.1111/ijd.16419. Epub 2022 Aug 28. PMID: 36030543.
• Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23. PMID: 35998300; PMCID: PMC9870217.
• Ellison PR, Statler A, Dragan K, Shepherd J, Chesney JM, Chung J, Fancy T, Ritchie KM, Moore L, Ellison MB. Optimizing Reversal of Muscle Relaxation with Sugammadex to Accelerate Discharge Readiness in Operative Laryngoscopy: A Randomized Clinical Trial. Ear Nose Throat J. 2023 Jan 2:1455613221132391. doi: 10.1177/01455613221132391. Epub ahead of print. PMID: 36594162.